{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005557","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2026-08-14T21:15:17+00:00","discovered_at":"2026-08-14T21:16:05.630549+00:00","generated_at":"2026-08-14T21:16:13.257049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BeyondSpring Q2 net loss $1.8M; ASCO data show 58% 24-month OS in post-ICI NSCLC","bullets":["Q2 2026 net loss $1.8M vs $1.9M YoY; cash and short-term investments $6.5M at June 30, 2026.","ASCO 2026 Phase 2 (n=47): median PFS 7.0 mo, ORR 18.2%, DCR 79.5%, 24-month OS 58.0%.","Leadership effective July 1, 2026: Min Qiu CEO, Jen Majeti Vice Chairman, Na Li CFO.","DUBLIN-4 planned confirmatory Phase 3: 442 patients, non-squamous EGFR-wild-type NSCLC post-ICI."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005557","json":"https://secwatch.observer/filing/0001171843-26-005557.json","markdown":"https://secwatch.observer/filing/0001171843-26-005557.md","text":"https://secwatch.observer/filing/0001171843-26-005557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326005557/0001171843-26-005557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184326005557/f8k_081426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T21:16:13.257049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}